Fwd: [] Ingestible Anti-Microbial Formula Kills Candida Species

[Guest guest]

tigerpaw2c <tigerpaw2c@...> wrote:

From: " tigerpaw2c " <tigerpaw2c@...>

Date: Tue, 03 Jan 2006 22:44:46 -0000

Subject: [] Ingestible Anti-Microbial Formula Kills Candida Species

January 03, 2006 10:15 AM US Eastern Timezone

Knock-out Technologies' Ingestible Anti-Microbial Formula Kills

Candida Species in Independent Laboratory Testing; Human Clinical

Studies to Commence

http://home.businesswire.com/portal/site/google/index.jsp?

ndmViewId=news_view & newsId=20060103005394 & newsLang=en

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Jan. 3, 2006-- Bowker,

president/CEO of Knock-Out Technologies Ltd., a wholly owned

subsidiary of eFoodSafety.com Inc. (OTCBB: EFSF), announced today

that its newly developed ingestible food-grade, anti-microbial

formula has shown a 100% kill of Candida Species, a major health

concern, in independent laboratory testing.

When our body defenses are compromised (immunosuppressed), fungal

infections become opportunistic and Candida is the most common of

these fungal infections. Candida infections have dramatically

increased in the hospital setting, notably the intensive care unit

and surgical intensive care unit, with associated morbidity and

mortality. The incidence in hospitals increased 500% from 1980 to

1989. Chronically ill patients, such as cancer patients undergoing

chemotherapy, steroid dependent transplant patients, HIV positive

patients, COPD patients, burn victims and patients with prosthetic

implants (valves, joints) are identified as patients at high risk to

contract Candida. There is also a high incidence among patients with

indwelling catheters and surgical wounds, as well as patients

receiving antibiotics or gastric acid-reducing treatments and also

patients who suffer from severe trauma, obesity, diabetes, and

alcohol or drug abuse. Developing new preventative and treatment

strategies has surfaced as a major priority in the medical

community. Currently available treatment and prophylaxis is not

without risk. A major adverse effect of current therapy is renal

toxicity.

Hospital, medical and surgical services now routinely give a

prophylactic treatment for their highest risk patients in special

care units. The $40,000 increase in the cost of critically ill

patients can be attributed to Candida infections. Candida Species in

the bloodstream has the highest mortality rate of all pathogens

isolated.

Ross-Gruden, president/CEO of eFoodSafety.com Inc., stated

that due to the favorable laboratory results, we are scheduled to

begin human clinical studies with our treatment for Candida mid-

February 2006. " We feel strongly that we as a company have an

obligation to improve outcomes in the treatment of patients with the

Candida infection and provide prophylaxis against future Candida

infections without the major side effects of currently available

treatments. Knock-Out Technologies continues to remain on the

cutting edge of revolutionary new products and ideas with which we

can improve our lives and do so without causing toxicity to humans, "

added Ross-Gruden.

About eFoodSafety.com Inc.

eFoodSafety.com Inc. is dedicated to improving food and health

conditions around the world through its innovative technologies. The

company's Knock-Out Technologies Ltd. subsidiary has developed an

environmentally safe sporicidal product formulated entirely of food-

grade components that eradicates anthrax and a germicidal product

that kills six major bacteria: E-coli, Listeria, Pseudomonas,

Salmonella, Staphylococcus and Streptococcus, Avian Influenza and

Black Mold. The sporicidal product has completed its final efficacy

laboratory study requisite for EPA registration. In the study, it

eradicated both Clostridium Sporogenes and Bacillus Subtilis with

100% efficacy on both hard and porous surfaces. The company's

MedElite Inc. subsidiary distributes clinically proven products to

physicians who then prescribe the products for their patients. It is

the exclusive U.S. and worldwide distributor of the Talsyn-

CI/bid Scar Cream that has been clinically proven to facilitate and

improve the appearance, redness and strength of scars

(www.talsyn.com). The company is also a distributor for Cinnergen

, a non-prescription liquid whole food nutritional supplement

that promotes healthy glucose metabolism (www.cinnergen.com), and

most recently became a distributor for Trimmendous, a weight

loss formula focusing on the body's 24-hour metabolic processes.

Safe Harbor Forward-Looking Statements

Statements contained in this release that are not strictly

historical are " forward-looking " statements within the meaning of

Section 27A of the Securities Act of 1933 as amended, and Section

21E of the Securities Exchange Act of 1934, as amended. The forward-

looking statements are made based on information available as of the

date hereof, and the company assumes no obligation to update such

forward-looking statements. Editors and investors are cautioned that

such forward-looking statements invoke risk and uncertainties and

the company's actual results may differ from these forward-looking

statements. Such risks and uncertainties include but are not limited

to demand for the company's products and services, our ability to

continue to develop markets, general economic conditions, our

ability to secure additional financing for the company and other

factors that may be more fully described in reports to shareholders

and periodic filings with the Securities and Exchange Commission.

Contacts

Redwood Consultants, LLC

Jens Dalsgaard, 415-884-0348

FAIR USE NOTICE: